ABSTRACT
BACKGROUND: Fragrance contact allergy is common and is currently screened for using the following European baseline series fragrance markers: fragrance mix (FM)I, FMII, Myroxylon pereirae and hydroxyisohexyl 3-cyclohexene carboxaldehyde. OBJECTIVES: To investigate the validity of patch testing using these fragrance markers in detecting fragrance allergy to 26 individual fragrance substances for which cosmetic ingredient labelling is mandatory within the European Union. METHODS: We conducted a retrospective review of the patch test records of all patients with eczema who underwent testing using the European baseline series, extended with the individual fragrance substances during the period from 2015 to 2016. RESULTS: Overall, 359 patients (17·2%) reacted to one or more allergens from the labelled fragrance substance series and/or a fragrance marker from the European baseline series. The allergens that were positive with the greatest frequencies were oxidized linalool [n = 154; 7·4%, 95% confidence interval (CI) 6·3-8·6], oxidized limonene (n = 89; 4·3%, 95% CI 3·4-5·2) and Evernia furfuracea (n = 44; 2·1%, 95% CI 1·5-2·8). Of the 319 patients who reacted to any of the labelled fragrance substances, only 130 (40·8%) also reacted to a baseline series fragrance marker. The sensitivity of our history-taking for detecting fragrance allergy was 25·7%. CONCLUSIONS: Given the evolving trends in fragrance allergy, patch testing with FMI, FMII, M. pereirae and hydroxyisohexyl 3-cyclohexene carboxaldehyde is no longer sufficient for screening for fragrance allergy.
Subject(s)
Cosmetics/adverse effects , Dermatitis, Allergic Contact/diagnosis , Odorants , Perfume/adverse effects , Acyclic Monoterpenes , Aldehydes , Allergens/adverse effects , Biomarkers , Cyclohexane Monoterpenes , Cyclohexanols/adverse effects , Cyclohexenes , Humans , Monoterpenes/adverse effects , Myroxylon , Patch Tests/methods , Patch Tests/standards , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Trityl Compounds/adverse effectsABSTRACT
BACKGROUND: For cosmetics, it is mandatory to label 26 fragrance substances, including all constituents of fragrance mix I (FM I) and fragrance mix II (FM II). Earlier reports have not included oxidized R-limonene [hydroperoxides of R-limonene (Lim-OOH)] and oxidized linalool [hydroperoxides of linalool (Lin-OOH)], and breakdown testing of FM I and FM II has mainly been performed in selected, mix-positive patients. OBJECTIVES: To report the prevalence of sensitization to the 26 fragrances, and to assess concomitant reactivity to FM I and/or FM II. METHODS: A cross-sectional study on consecutive dermatitis patients patch tested with the 26 fragrances and the European baseline series from 2010 to 2015 at a single university clinic was performed. RESULTS: Of 6004 patients, 940 (15.7%, 95%CI: 14.7-16.6%) were fragrance-sensitized. Regarding the single fragrances, most patients were sensitized to Lin-OOH (3.9%), Evernia furfuracea (3.0%), Lim-OOH (2.5%), and hydroxyisohexyl 3-cyclohexene carboxaldehyde (2.1%). Significantly fewer patients were 'FM I-positive and constituent-positive' than 'FM II-positive and constituent-positive' (32.7% versus 57.0%, p < 0.0001). Additionally, significantly more patients were 'FM II-negative but constituent-positive' than 'FM I-negative but constituent-positive' (12.4% versus 3.2%, p = 0.0008). CONCLUSIONS: Non-mix fragrances are the most important single fragrance allergens among consecutive patients. The test concentration of the single FM I constituents should be increased when possible.
Subject(s)
Allergens/adverse effects , Dermatitis, Allergic Contact/epidemiology , Perfume/adverse effects , Acyclic Monoterpenes , Adult , Aldehydes/adverse effects , Cross-Sectional Studies , Cyclohexanols/adverse effects , Cyclohexenes/adverse effects , Denmark/epidemiology , Dermatitis, Allergic Contact/etiology , Female , Humans , Lichens , Limonene , Male , Middle Aged , Monoterpenes/adverse effects , Prevalence , Terpenes/adverse effects , Trityl Compounds/adverse effectsABSTRACT
Neuropathic pain is a debilitating, chronic condition with a significant unmet need for effective treatment options. Recent studies have demonstrated that in addition to neurons, non-neuronal cells such as microglia contribute to the initiation and maintenance of allodynia in rodent models of neuropathic pain. The Ca2+- activated K+ channel, KCa3.1 is critical for the activation of immune cells, including the CNS-resident microglia. In order to evaluate the role of KCa3.1 in the maintenance of mechanical allodynia following peripheral nerve injury, we used senicapoc, a stable and highly potent KCa3.1 inhibitor. In primary cultured microglia, senicapoc inhibited microglial nitric oxide and IL-1ß release. In vivo, senicapoc showed high CNS penetrance and when administered to rats with peripheral nerve injury, it significantly reversed tactile allodynia similar to the standard of care, gabapentin. In contrast to gabapentin, senicapoc achieved efficacy without any overt impact on locomotor activity. Together, the data demonstrate that the KCa3.1 inhibitor senicapoc is effective at reducing mechanical hypersensitivity in a rodent model of peripheral nerve injury.
Subject(s)
Acetamides/pharmacology , Hyperalgesia/complications , Hyperalgesia/drug therapy , Intermediate-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors , Peripheral Nerve Injuries/complications , Potassium Channel Blockers/pharmacology , Trityl Compounds/pharmacology , Acetamides/adverse effects , Acetamides/pharmacokinetics , Acetamides/therapeutic use , Animals , CHO Cells , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , Drug Stability , Humans , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Locomotion/drug effects , Microglia/drug effects , Microglia/metabolism , Potassium/metabolism , Potassium Channel Blockers/adverse effects , Potassium Channel Blockers/pharmacokinetics , Potassium Channel Blockers/therapeutic use , Rats , Trityl Compounds/adverse effects , Trityl Compounds/pharmacokinetics , Trityl Compounds/therapeutic useSubject(s)
Acetamides/adverse effects , Acetamides/therapeutic use , Anemia, Sickle Cell/classification , Anemia, Sickle Cell/drug therapy , Trityl Compounds/adverse effects , Trityl Compounds/therapeutic use , Anemia, Sickle Cell/blood , Hemoglobin, Sickle/metabolism , Humans , Pain/chemically induced , Phenotype , Randomized Controlled Trials as TopicABSTRACT
Red blood cell (RBC) hydration is regulated in part by the Ca(2+) -activated K(+) efflux (Gardos) channel. Senicapoc selectively blocks potassium efflux through the Gardos channel, reducing RBC dehydration and haemolysis, and increasing haemoglobin levels in sickle cell disease (SCD). This randomized, placebo-controlled trial was designed to determine the safety and clinical efficacy of senicapoc in SCD patients. One hundred and forty-five patients were randomized to receive senicapoc and 144 patients to receive placebo for 52 weeks. Consistent with a previous study, patients in the senicapoc group had significantly increased haematocrit, haemoglobin, and decreased numbers of both dense erythrocytes and reticulocytes when compared to the placebo group. The unblinded Data Monitoring Committee terminated this study early due to a lack of efficacy when it determined that, despite improvements in anaemia and haemolysis, no significant improvement in the rate of sickle cell painful crises was observed in patients treated with senicapoc compared to those on placebo (0·38 vs. 0·31, respectively). Comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not statistically significant. Nausea and urinary tract infections occurred more frequently in the senicapoc group than placebo. Serious adverse events were similar in the two groups.
Subject(s)
Acetamides/therapeutic use , Anemia, Sickle Cell/drug therapy , Antisickling Agents/therapeutic use , Erythrocyte Aging/drug effects , Hemolysis/drug effects , Trityl Compounds/therapeutic use , Acetamides/administration & dosage , Acetamides/adverse effects , Acetamides/blood , Adolescent , Adult , Aged , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/complications , Antisickling Agents/administration & dosage , Antisickling Agents/adverse effects , Antisickling Agents/blood , Double-Blind Method , Drug Administration Schedule , Female , Hematocrit , Humans , Intermediate-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors , Male , Middle Aged , Pain/etiology , Pain/prevention & control , Treatment Outcome , Trityl Compounds/administration & dosage , Trityl Compounds/adverse effects , Trityl Compounds/blood , Young AdultABSTRACT
Sickle cell disease (SCD) is characterized by hemolytic as well as vaso-occlusive complications. The development of treatments for this inherited disease is based on an understanding of its pathophysiology. Polymerization of sickle hemoglobin is dependent on several independent factors, including the intracellular hemoglobin concentration. The hydration state (and intracellular hemoglobin concentration) of the sickle erythrocyte depends on the loss of solute and osmotically obliged water through specific pathways. Senicapoc (also known as ICA-17043) is a potent blocker of the Gardos channel, a calcium-activated potassium channel of intermediate conductance, in the red blood cell. Preclinical studies and studies in transgenic models of SCD show that inhibition of potassium efflux through the Gardos channel is associated with an increased hemoglobin level, decreased dense cells and decreased hemolysis. Senicapoc is well tolerated when administered to SCD patients and produces dose-dependent increases in hemoglobin and decreases in markers of hemolysis. Despite the lack of a reduction in the frequency of pain episodes, the increasing recognition that hemolysis contributes to the development of several SCD-related complications suggests that by decreasing hemolysis, senicapoc may yet prove to be beneficial in this disease.
Subject(s)
Acetamides/therapeutic use , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/drug therapy , Hemolysis/drug effects , Trityl Compounds/therapeutic use , Acetamides/adverse effects , Acetamides/chemistry , Acetamides/toxicity , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/physiopathology , Animals , Animals, Genetically Modified , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Humans , Mice , Trityl Compounds/adverse effects , Trityl Compounds/chemistry , Trityl Compounds/toxicitySubject(s)
Coloring Agents/adverse effects , Melanoma/surgery , Skin Neoplasms/surgery , Trityl Compounds/adverse effects , Urticaria/chemically induced , Anaphylaxis/chemically induced , Humans , Injections, Intradermal , Lymphatic Metastasis , Male , Melanoma/pathology , Rosaniline Dyes/adverse effects , Skin Neoplasms/pathologyABSTRACT
Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration. Because hemoglobin S polymerization is profoundly influenced by intracellular hemoglobin concentration, senicapoc could improve sickle RBC survival. In a 12-week, multicenter, phase 2, randomized, double-blind, dose-finding study, we evaluated senicapoc's safety and its effect on hemoglobin level and markers of RBC hemolysis in sickle cell anemia patients. The patients were randomized into 3 treatment arms: placebo; low-dose (6 mg/day) senicapoc; and high-dose (10 mg/day) senicapoc. For the primary efficacy end point (change in hemoglobin level from baseline), the mean response to high-dose senicapoc treatment exceeded placebo (6.8 g/L [0.68 g/dL] vs 0.1 g/L [0.01 g/dL], P < .001). Treatment with high-dose senicapoc also produced significant decreases in such secondary end points as percentage of dense RBCs (-2.41 vs -0.08, P < .001); reticulocytes (-4.12 vs -0.46, P < .001); lactate dehydrogenase (-121 U/L vs -15 U/L, P = .002); and indirect bilirubin (-1.18 mg/dL vs 0.12 mg/dL, P < .001). Finally, senicapoc was safe and well tolerated. The increased hemoglobin concentration and concomitant decrease in the total number of reticulocytes and various markers of RBC destruction following senicapoc administration suggests a possible increase in the survival of sickle RBCs. This study is registered at http://clinicaltrials.gov as NCT00040677.
Subject(s)
Acetamides/adverse effects , Acetamides/therapeutic use , Anemia, Sickle Cell/drug therapy , Potassium Channel Blockers/adverse effects , Potassium Channel Blockers/therapeutic use , Trityl Compounds/adverse effects , Trityl Compounds/therapeutic use , Acetamides/blood , Adolescent , Adult , Female , Humans , Male , Middle Aged , Potassium Channel Blockers/blood , Time Factors , Treatment Outcome , Trityl Compounds/bloodABSTRACT
STUDY OBJECTIVE: To determine the dose tolerance, safety, and pharmacokinetics of a single oral dose of ICA-17043 in patients with sickle cell disease. DESIGN: Phase I, randomized, double-blind, placebo-controlled, single-dose, dose-escalation study. SETTING: Four university medical centers. PATIENTS: Twenty-eight patients with sickle cell disease, aged 18-60 years, who were otherwise healthy and in a noncrisis state. INTERVENTION: Patients in three separate dose cohorts--50 mg, 100 mg, and 150 mg--received single doses of ICA-17043 or placebo. MEASUREMENTS AND MAIN RESULTS: The mean area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)) for ICA-17043 increased in a dose-related manner (11,827, 19,697, and 30,676 ng.hr/ml for 50, 100, and 150 mg, respectively). Overall mean half-life was 12.8 days. Mean peak plasma concentrations rose between the 50- and 100-mg dose levels but plateaued at 150 mg (59.1, 108.7, and 109.1 ng/ml, respectively). Weekly pharmacokinetic and safety assessments were conducted in each patient during the follow-up phase for 56 days. No dose-limiting adverse events were noted in any of the patients. CONCLUSION: Total systemic exposure of ICA-17043 after a single oral dose, as measured by AUC(0-infinity), increased nearly proportionally with the dose. The rate of absorption, however, appeared to be delayed at doses greater than 100 mg. With the long half-life of ICA-17043 demonstrated in this study, once-daily dosing is probably adequate to maintain steady-state plasma concentrations. In addition, single doses of ICA-17043 were well tolerated.
Subject(s)
Acetamides/pharmacokinetics , Anemia, Sickle Cell/blood , Potassium Channels, Calcium-Activated/antagonists & inhibitors , Trityl Compounds/pharmacokinetics , Acetamides/adverse effects , Acetamides/blood , Adult , Anemia, Sickle Cell/drug therapy , Double-Blind Method , Humans , Middle Aged , Trityl Compounds/adverse effects , Trityl Compounds/bloodABSTRACT
A 36-year-old man was admitted to hospital with increasing breathlessness. He had been exposed to triphenylmethane triisocyanate. Pulmonary function tests demonstrated physiological abnormalities consistent with both asthma and alveolitis. Exposure to less common isocyanates may not be immediately apparent. Asthma developing after isocyanate exposure is well recognized. Pneumonitis is a relatively rare complication. Measurement of gas transfer may be helpful in the investigation of isocyanate toxicity.
Subject(s)
Adhesives/adverse effects , Alveolitis, Extrinsic Allergic/etiology , Asthma/etiology , Cyanates/adverse effects , Isocyanates/metabolism , Occupational Diseases/etiology , Trityl Compounds/adverse effects , Trityl Compounds/metabolism , Adult , Humans , MaleSubject(s)
Abietanes , Dermatitis, Contact/etiology , Organophosphates , Paper , Phenanthrenes , Aniline Compounds/adverse effects , Diterpenes/adverse effects , Eczema/chemically induced , Formaldehyde/adverse effects , Humans , Organophosphorus Compounds/adverse effects , Thiourea/adverse effects , Trityl Compounds/adverse effectsSubject(s)
Dermatitis, Contact/etiology , Rosaniline Dyes/adverse effects , Adult , Female , Humans , Male , Middle Aged , Trityl Compounds/adverse effectsABSTRACT
The problem of iatrogenic carcinogenesis is treated with special reference to dermatological dispensings. The problem of arsenic as a drug, of cytostatic drugs, antimycotic drugs and external dispensings is discussed. The chance to induce cancer by medical treatment in dermatology is considered to be very low since arsenic has been eliminated.
Subject(s)
Skin Neoplasms/chemically induced , Acridines/adverse effects , Animals , Anthraquinones/adverse effects , Arsenic/adverse effects , Cyclophosphamide/adverse effects , Humans , Phenols/adverse effects , Psoriasis/drug therapy , Trityl Compounds/adverse effectsABSTRACT
Clotrimazole (Bay b 5097) is a new synthetic antifungal drug with in vitro activity against Candida spp., Torulopsis glabrata, and Saccharomyces spp. Pharmacological studies in man after the oral administration of 1.5 and 3 g of clotrimazole produced mean peak concentrations in the serum of 1.16 and 1.29 mug/ml, respectively, 2 hr after administration. In six patients taking 1.5 g of clotrimazole every 6 hr, there was a progressive decline in the serum concentrations after administration of a dose on days 1, 4, and 8. Nine other patients begun on a similar schedule manifested gastrointestinal symptoms attributed to the clotrimazole and were unable to complete the study. Concentrations of active drug in the urine were less than 1% of the administered dose.